Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.
暂无分享,去创建一个
D. Katzenstein | P. Sax | E. Daar | A. Collier | M. Fischl | C. Budhathoki | Kimberly Smith | C. Godfrey | C. Venuto | K. Mollan | G. Morse | C. Tierney | Q. Ma
[1] Guoxing Soon,et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). , 2012, AIDS patient care and STDs.
[2] D. Katzenstein,et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. , 2011, The Journal of infectious diseases.
[3] D. Katzenstein,et al. Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 , 2011, Annals of Internal Medicine.
[4] Lynne Peeples,et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. , 2009, The New England journal of medicine.
[5] S. Hammer,et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.
[6] Peter Reiss,et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.
[7] Lynne Peeples,et al. Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.
[8] D. Kuritzkes,et al. Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy: Results of ACTG A5095 , 2007, Journal of acquired immune deficiency syndromes.
[9] R. Bosch,et al. Pretreatment Factors Associated With 3-Year (144-Week) Virologic and Immunologic Responses to Potent Antiretroviral Therapy , 2007, Journal of acquired immune deficiency syndromes.
[10] M. Fischl,et al. Integration of Atazanavir into an Existing Liquid Chromatography UV Method for Protease Inhibitors: Validation and Application , 2007, Therapeutic drug monitoring.
[11] M. Hirsch,et al. Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects: Results From ACTG 384 , 2006, Journal of acquired immune deficiency syndromes.
[12] Victor De Gruttola,et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. , 2003, The New England journal of medicine.
[13] Anne M Johnson,et al. Virologic, Immunologic, and Clinical Response to Highly Active Antiretroviral Therapy: the Gender Issue Revisited , 2003, Journal of acquired immune deficiency syndromes.
[14] G. Beall,et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.
[15] A. Wu,et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments , 2000, AIDS care.
[16] J. J. Henning,et al. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.
[17] Huldrych F. Günthard,et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. , 2012, JAMA.
[18] J. Bartlett,et al. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to reduce Perinatal HIV-1Transmission in the United States , 2003 .